-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Downgrades Sarepta Therapeutics to Neutral, Lowers Price Target to $28

Benzinga·06/16/2025 17:47:31
Listen to the news
B of A Securities analyst Tazeen Ahmad downgrades Sarepta Therapeutics (NASDAQ:SRPT) from Buy to Neutral and lowers the price target from $76 to $28.